Literature DB >> 21288814

Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age.

Danuta M Skowronski1, Travis S Hottes, Janet E McElhaney, Naveed Z Janjua, Suzana Sabaiduc, Tracy Chan, Beth Gentleman, Dale Purych, Jennifer Gardy, David M Patrick, Robert C Brunham, Gaston De Serres, Martin Petric.   

Abstract

BACKGROUND: Pandemic H1N1 (pH1N1) surveillance data showed lower attack rates but higher risk of severe outcomes with advanced age. We explored immuno-epidemiologic correlates of surveillance findings including humoral and cell-mediated immunity (CMI).
METHODS: In an age-based design, ∼100 banked/residual sera per 10-year age stratum were assessed by hemagglutination inhibition (HI) and microneutralization (MN) assays for preexisting antibody to pH1N1 and recent seasonal H1N1 and H3N2 strains. In a separate birth cohort design defined by childhood influenza A/subtype priming (1919-1929: H1N1; 1945-1949: H1N1; 1958-1960: H2N2; 1969-1970: H3N2; 1978-1989: H3N2/H1N1), whole blood was collected from up to 50 volunteers per birth cohort. The ratio of Th1(IFN-γ):Th2(IL-10) cytokine responses was evaluated in vitro.
RESULTS: Antibody to seasonal viruses was highest in school-age children. Cross-reactive HI/MN antibody to pH1N1 was low among participants <70 years of age (yoa; 6%/4% ≥ 40), but seroprevalence increased at 70-79 yoa (27%/6%), increased even more at 80-89 yoa (65%/47%), and was highest at ≥90 yoa (88%/76%). CMI to pH1N1 was evident in all 5 birth cohorts but was lower compared with seasonal strains. There was little differentiation by subtype priming, but the Th1:Th2 ratio for all viruses dropped significantly in the 2 oldest cohorts.
CONCLUSIONS: Preexisting antibody may have protected the very old from pH1N1 infection, while diminished CMI may have contributed to greater severity once infected. In the young, cross-reactive pH1N1 antibody was mostly absent, while more intact CMI may have protected against severe outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288814      PMCID: PMC3071066          DOI: 10.1093/infdis/jiq039

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period.

Authors:  Caterina Rizzo; Maria Cristina Rota; Antonino Bella; Valeria Alfonsi; Silvia Declich; Maria Grazia Caporali; Alessia Ranghiasci; Giulia Lapini; Simona Piccirella; Stefania Salmaso; Emanuele Montomoli
Journal:  Vaccine       Date:  2010-03-20       Impact factor: 3.641

2.  Standardization and validation of assays determining cellular immune responses against influenza.

Authors:  Karlijn Gijzen; Wai Ming Liu; Ildikó Visontai; Fredrik Oftung; Sylvie van der Werf; Gro Ellen Korsvold; Inge Pronk; Ingeborg S Aaberge; Anna Tütto; Istvan Jankovics; Mate Jankovics; Beth Gentleman; Janet E McElhaney; Ernst C Soethout
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

3.  Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus.

Authors:  Wenwei Tu; Huawei Mao; Jian Zheng; Yinping Liu; Susan S Chiu; Gang Qin; Ping-Lung Chan; Kwok-Tai Lam; Jing Guan; Lijuan Zhang; Yi Guan; Kwok-Yung Yuen; J S Malik Peiris; Yu-Lung Lau
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

4.  Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin.

Authors:  Manabu Igarashi; Kimihito Ito; Reiko Yoshida; Daisuke Tomabechi; Hiroshi Kida; Ayato Takada
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

5.  Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Authors:  Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham
Journal:  PLoS Med       Date:  2010-04-06       Impact factor: 11.069

6.  Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

Authors:  Elizabeth Miller; Katja Hoschler; Pia Hardelid; Elaine Stanford; Nick Andrews; Maria Zambon
Journal:  Lancet       Date:  2010-01-21       Impact factor: 79.321

7.  Yearly influenza vaccinations: a double-edged sword?

Authors:  Rogier Bodewes; Joost H C M Kreijtz; Guus F Rimmelzwaan
Journal:  Lancet Infect Dis       Date:  2009-10-30       Impact factor: 25.071

8.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Authors:  Kathy Hancock; Vic Veguilla; Xiuhua Lu; Weimin Zhong; Eboneé N Butler; Hong Sun; Feng Liu; Libo Dong; Joshua R DeVos; Paul M Gargiullo; T Lynnette Brammer; Nancy J Cox; Terrence M Tumpey; Jacqueline M Katz
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

9.  The wages of original antigenic sin.

Authors:  David M Morens; Donald S Burke; Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

10.  Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza?

Authors:  Tom Reichert; Gerardo Chowell; Hiroshi Nishiura; Ronald A Christensen; Jonathan A McCullers
Journal:  BMC Infect Dis       Date:  2010-01-07       Impact factor: 3.090

View more
  58 in total

1.  GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.

Authors:  Hayedeh Behzad; Anke L W Huckriede; Laura Haynes; Beth Gentleman; Krysta Coyle; Jan C Wilschut; Tobias R Kollmann; Steven G Reed; Janet E McElhaney
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  Persistence of immunogenicity of a monovalent influenza virus A/H1N1 2009 vaccine in healthy volunteers.

Authors:  Yi-Chun Lai; Kuen-Cheh Yang; Szu-Min Hsieh; Chien-An Yao; Long-Teng Lee; Kuo-Chin Huang
Journal:  Clin Vaccine Immunol       Date:  2012-01-18

3.  Integration of immunity with physical and cognitive function in definitions of successful aging.

Authors:  Patricia Griffin; Joshua J Michel; Kristy Huysman; Alison J Logar; Abbe N Vallejo
Journal:  Aging Dis       Date:  2012-02-27       Impact factor: 6.745

4.  Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.

Authors:  Danuta M Skowronski; Travis S Hottes; Naveed Z Janjua; Dale Purych; Suzana Sabaiduc; Tracy Chan; Gaston De Serres; Jennifer Gardy; Janet E McElhaney; David M Patrick; Martin Petric
Journal:  CMAJ       Date:  2010-10-18       Impact factor: 8.262

5.  Pandemic and seasonal human influenza virus infections in domestic cats: prevalence, association with respiratory disease, and seasonality patterns.

Authors:  A Ali; J B Daniels; Y Zhang; A Rodriguez-Palacios; K Hayes-Ozello; L Mathes; C-W Lee
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

6.  Seasonal Influenza Infections and Cardiovascular Disease Mortality.

Authors:  Jennifer L Nguyen; Wan Yang; Kazuhiko Ito; Thomas D Matte; Jeffrey Shaman; Patrick L Kinney
Journal:  JAMA Cardiol       Date:  2016-06-01       Impact factor: 14.676

Review 7.  The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines.

Authors:  Janet E McElhaney; Xin Zhou; H Keipp Talbot; Ernst Soethout; R Chris Bleackley; David J Granville; Graham Pawelec
Journal:  Vaccine       Date:  2012-01-27       Impact factor: 3.641

8.  Patterns of spread of influenza A in Canada.

Authors:  Daihai He; Jonathan Dushoff; Raluca Eftimie; David J D Earn
Journal:  Proc Biol Sci       Date:  2013-09-11       Impact factor: 5.349

9.  Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.

Authors:  Arun Kumar; Janet E McElhaney; Lisa Walrond; Terry D Cyr; Shahzma Merani; Tobias R Kollmann; Scott A Halperin; David W Scheifele
Journal:  Hum Vaccin Immunother       Date:  2017-06-21       Impact factor: 3.452

Review 10.  HSC Aging and Senescent Immune Remodeling.

Authors:  Michael D Denkinger; Hanna Leins; Reinhold Schirmbeck; Maria Carolina Florian; Hartmut Geiger
Journal:  Trends Immunol       Date:  2015-11-21       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.